Tandem Diabetes Care (TNDM) Set to Announce Quarterly Earnings on Thursday

Tandem Diabetes Care (NASDAQ:TNDM) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.2453) per share and revenue of $265.85 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Thursday, August 6th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.01. Tandem Diabetes Care had a negative return on equity of 45.97% and a negative net margin of 6.08%. The firm had revenue of $254.56 million during the quarter, compared to the consensus estimate of $254.99 million. During the same quarter last year, the company posted ($0.78) EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. On average, analysts expect Tandem Diabetes Care to post ($0.66) EPS for the current fiscal year and $0.09 EPS for the next fiscal year.

Tandem Diabetes Care Stock Down 2.3%

Shares of NASDAQ TNDM opened at $18.67 on Tuesday. Tandem Diabetes Care has a 12 month low of $12.26 and a 12 month high of $29.65. The company has a current ratio of 3.18, a quick ratio of 2.65 and a debt-to-equity ratio of 4.62. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -20.08 and a beta of 1.66. The business has a 50-day moving average of $17.95 and a 200-day moving average of $18.93.

Insiders Place Their Bets

In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of the business’s stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $19.15, for a total value of $32,555.00. Following the completion of the sale, the director directly owned 24,434 shares of the company’s stock, valued at $467,911.10. The trade was a 6.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. UBS Group started coverage on shares of Tandem Diabetes Care in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 target price on the stock. Citigroup cut their price target on shares of Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, September 30th. William Blair assumed coverage on shares of Tandem Diabetes Care in a research note on Friday, August 21st. They issued an “outperform” rating for the company. Truist Financial decreased their price target on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, September 24th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $26.00 price objective (down from $30.00) on shares of Tandem Diabetes Care in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Tandem Diabetes Care has an average rating of “Hold” and an average price target of $27.08.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.